Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
Open Access
- 1 August 2012
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (suppl_6), vi46-vi51
- https://doi.org/10.1093/annonc/mds195
Abstract
Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy. Duration of response is usually short, with rapid relapse very common and median survival of just 13 months. The newly approved agent eribulin has shown a survival benefit in patients who had previously been treated with anthracycline- or taxane-containing regimens, including in patients with TNBC. Platinum-based regimens are an emerging option for patients with BRCA1 mutation, and newer targeted agents such as anti-angiogenic treatment with bevacizumab or anti-epidermal growth factor receptor treatment with cetuximab, have shown some benefit in combination therapy. However, there remains an urgent unmet need for improved targeted agents for this patient population. Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs.Keywords
This publication has 58 references indexed in Scilit:
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancerBritish Journal of Cancer, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerThe New England Journal of Medicine, 2011
- Triple-Negative Breast CancerThe Cancer Journal, 2010
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI Journal of the National Cancer Institute, 2009
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal SubtypesClinical Cancer Research, 2009
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005